ADC	antibody drug conjugate
ADCC	antibody dependent cellular cytotoxicity,
ADCP	antibody dependent cellular phagocytosis
APC	antigen presenting cell
ASCT	autologous stem cell transplantation
BCMA	B cell maturation antigen
CDC	complement dependent cytotoxicity
CR	complete remission
d/D	dexamethasone
Dara	daratumumab
DIRA	daratumumab specific immunofixation reflex assay
DM1	mertansine
DM4	ravtansine
EAT-2	Ewing’s sarcoma-associated transcript 2
Elo	elotuzumab
EMA	European Medicines Agency
FDA	Food and Drug Administration
HR	hazard ratio
IMiD	immunomodulatory drug
IMWG	International Myeloma Working Group
IRR	infusion related reaction
Isa	isatuximab
K	carfilzomib
m	month
MMAF	monomethyl auristatin F
MoAb	monoclonal antibody
MRD	minimal residual disease
NDMM	newly diagnosed multiple myeloma
NK	natural killer
NR	not reached
ORR	overall response rate
P	pomalidomide
PI	proteasome inhibitor
PFS	progression free survival
PN	peripheral neuropathy
R	lenalidomide
RBC	red blood cell
RRMM	relapsed/refractory multiple myeloma
SLAMF-7	Signaling Lymphocyte Activation Molecule Family 7
TE	transplant eligible
TE	transplant eligible
V	bortezomib
VGPR	very good partial remission